Evaxion Announces Data From Interim Analysis Of Phase 2 Trial Of EVX-01 Showing 69% Overall Response Rate; 15 Of 16 Patients Had Reduction Of Their Tumors
Portfolio Pulse from Benzinga Newsdesk
Evaxion Biotech announced interim results from its Phase 2 trial of EVX-01, showing a 69% overall response rate with 15 out of 16 patients experiencing tumor reduction.
September 09, 2024 | 12:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Evaxion Biotech's Phase 2 trial of EVX-01 demonstrated a 69% overall response rate, with significant tumor reduction in most patients, indicating positive clinical progress.
The positive interim results from the Phase 2 trial of EVX-01 suggest promising efficacy, likely boosting investor confidence and potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100